Publications by authors named "J Schwaab"
Due to insufficient climate action over the past decade, it is increasingly likely that 1.5 °C of global warming will be exceeded - at least temporarily - in the 21 century. Such a temporary temperature overshoot carries additional climate risks which are poorly understood.
View Article and Find Full Text PDFArticle Synopsis
- Momelotinib, a newly approved JAK1/2 inhibitor, shows promise in treating myelofibrosis (MF) patients, particularly those with anemia, improving hemoglobin and platelet levels over a median treatment duration of 12 weeks.
- In a study of 60 MF patients, 39% of transfusion-dependent individuals experienced reduced transfusion needs, with 21% achieving transfusion independence in about 4 weeks.
- While momelotinib is effective, it also presented safety concerns, with 17% of patients experiencing creatinine increases, and some patients discontinued treatment due to side effects or worsening symptoms.
Purpose Of Review: In this review, we aim to explore the optimal approach to patients presenting with eosinophilia, considering recent advances in diagnostic and therapeutic strategies. Specifically, we focus on the integration of novel therapies into clinical practice to improve patient outcomes.
Recent Findings: Advanced insights into the clinical and genetic features of eosinophilic disorders have prompted revisions in diagnostic criteria by the World Health Organization classification (WHO-HAEM5) and the International Consensus Classification (ICC).
Article Synopsis
- Hypersensitivity reactions (HR) are common in mastocytosis, a condition analyzed using data from the European Competence Network on Mastocytosis (ECNM), involving 2485 adults.
- About 38.1% of patients reported HR, with Hymenoptera venoms being the primary trigger for cutaneous mastocytosis and indolent systemic mastocytosis, while drug reactions were more common in advanced systemic mastocytosis.
- Key risk factors for HR include lower tryptase levels, minimal mast cell infiltration in bone marrow, and a diagnosis of indolent systemic mastocytosis, with new reactions occurring in 4.8% of patients over four years.
Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most specific serum parameter.
View Article and Find Full Text PDF